SummaryRMgm-4313
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 28787542 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. yoelii |
Parent strain/line | P. y. yoelii 17XNL |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Muñoz EE, Lindner SE |
Name Group/Department | Department of Biochemistry and Molecular Biology, Center for Malaria Research |
Name Institute | Pennsylvania State University |
City | University Park, PA |
Country | USA |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-4313 |
Principal name | pyalba4 |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | No differences in total gametocytemia, sex ratio, or mature-immature gametocyte ratio; two-fold increase in the number of activated male gametes. |
Fertilization and ookinete | Not tested |
Oocyst | No significant differences in the prevalence of mosquito infection, oocyst numbers, nor in the total number of sporozoites per infected mosquito (the sum of midgut and salivary gland sporozoites) A significant effect was observed upon the semi-synchronous egress of sporozoites from oocysts in the midgut and their arrival in the salivary gland; pyalba4- parasites continue to egress from the oocysts over time and are capable of invading the salivary gland and are highly infectious to mice. |
Sporozoite | A significant effect was observed upon the semi-synchronous egress of sporozoites from oocysts in the midgut and their arrival in the salivary gland; pyalba4- parasites continue to egress from the oocysts over time and are capable of invading the salivary gland and are highly infectious to mice. |
Liver stage | Not different from wild type |
Additional remarks phenotype | Mutant/mutation Other mutants |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PY17X_1366000 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1347500 | ||||||||||||||||||||||||
Gene product | DNA/RNA-binding protein Alba 4 | ||||||||||||||||||||||||
Gene product: Alternative name | ALBA4 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |